Beta-O2 Technologies

Company Overview

Snapshot

Founded in January 2004, Beta-O2 Technologies operates with 11–50 employees. The company has raised $8.22 million across 6 funding rounds from 5 investors. In August 2025, Beta-O2 Technologies ceased to operate.

Business overview

Beta-O2 Technologies is a biomedical company focused on developing an implantable bioreactor, the Air, for the treatment of type 1 diabetes. This small medical device, implanted through a minimally invasive procedure, contains islets of Langerhans and aims to eliminate the need for insulin injections and continuous glucose monitoring, while also reducing the risk of hypoglycemic episodes. The device requires patients to periodically refill the air using a dedicated replenishing device. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Medical Devices industries, with a focus on biomaterials, tissue engineering, and medical treatment therapeutics for patients and healthcare providers.

Company Intelligence Q&A

What was the most recent significant corporate event for Beta-O2 Technologies?

In August 2025, Beta-O2 Technologies ceased to operate, marking the end of its business activities.

When did Beta-O2 Technologies begin human trials for its artificial pancreas?

In March 2020, Beta-O2 Technologies announced plans to begin human trials for its new artificial pancreas.

Which investors participated in the January 2018 funding round?

In January 2018, Sherpa InnoVentures participated in a funding round for Beta-O2 Technologies.

What was the outcome of the collaboration between Beta-O2 Technologies and MIT in April 2018?

In April 2018, a collaboration between Beta-O2 Technologies and the Massachusetts Institute of Technology led to a breakthrough in implanted islet cell technology, providing living pancreatic islet cells with their own oxygen supply through an implantable device.

Which investor participated in the September 2017 funding round?

In September 2017, Internet Research Institute (IRI) participated in a funding round for Beta-O2 Technologies.